ArticleJournal of molecular medicine (Berlin, Germany)2025
Nicotinamide riboside alleviates sepsis-induced acute kidney injury by suppressing ferroptosis.
Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Crosstalk of regulated cell death pathways in sepsis-associated acute kidney injury: implications for therapy.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Sepsis-induced acute kidney injury (SAKI) is the predominant type of acute kidney injury encountered in intensive care units. Nicotinamide riboside (NR) improves kidney function in acute and chronic kidney diseases; however, its role in SAKI and the underlying mechanism remain unclear. We aimed to investigate the inhibitory effects of NR on ferroptosis in SAKI and explored the potential mechanisms involved. Cecal ligation and puncture markedly reduced SIRT1 expression in vivo, impaired renal function, decreased glutathione (GSH) activity, and glutathione peroxidase 4 (GPX4) expression, and increased the expression levels of acyl-CoA synthetase long-chain family member 4 (ACSL4), ferritin heavy chain (FTH), and 4-hydroxynonenal (4-HNE). Pretreatment with NR ameliorated these changes, whereas the protective effects of NR were reversed by treatment with the selective SIRT1 inhibitor, EX527. NR promoted SIRT1 expression in vitro and restored lipopolysaccharide (LPS)-induced downregulation of GPX4 and upregulation of ACSL4, FTH, and 4-HNE in human renal tubular epithelial (HK-2) cells. Meanwhile, NR treatment increased GSH activity and reduced the production of reactive oxygen species. EX527 treatment or SIRT1 knockdown abolished the NR-mediated ferroptosis alleviation in vitro. Additionally, we discovered that SIRT1 overexpression mimicked the protective function of NR in inhibiting ferroptosis in LPS-stimulated HK-2 cells. In light of our study findings, we concluded that NR suppressed ferroptosis by upregulating SIRT1 expression, thereby mitigating AKI induced by sepsis. This study provides a foundation for further research on SAKI and identifies potential therapeutic targets. KEY MESSAGES: NR ameliorated sepsis-induced acute kidney injury by suppressing ferroptosis. NR attenuated SIRT1 expression, resulting in ferroptosis inhibition. Using EX527 or SIRT1 knockdown abolished NR-mediated ferroptosis alleviation. SIRT1 overexpression mimicked NR's protective function in inhibiting ferroptosis.
Indexed as
Identifiers
41419644What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.